Core binding factor acute myeloid leukemia: The impact of age, leukocyte count, molecular findings and minimal residual disease

European Journal of Haematology

Volumn 91, Issue 3, 2013, Pages 209-218

  Hoyos, Montserrat ^a,b   Nomdedeu, Josep F ^a   Esteve, Jordi ^a   Duarte, Rafael ^a   Ribera, Josep M ^a   Llorente, Andreu ^a   Escoda, Lourdes ^a   Bueno, Javier ^a   Tormo, Mar ^a   Gallardo, David ^a   de Llano, Maria Paz Queipo ^a   Martí, Josep M ^a   Aventín, Anna ^a   Mangues, Ramón ^c   Brunet, Salut ^a   Sierra, Jorge ^a,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d BANC DE SANG I TEIXITS   (Spain)

Author keywords

Acute myeloid leukemia; Biologic and molecular prognostic factors; Core binding factors

Indexed keywords

CORE BINDING FACTOR BETA; CYTARABINE; DNA; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BAALC GENE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONSOLIDATION CHEMOTHERAPY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GENE; GENE OVEREXPRESSION; GROUPS BY AGE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MN1 GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK;

ACUTE MYELOID LEUKEMIA; BIOLOGIC AND MOLECULAR PROGNOSTIC FACTORS; CORE BINDING FACTORS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84881665264     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12130     Document Type: Article

References (31)

1. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004;22:1087-94.
2. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-75.
3. Dombret H, Preudhomme C, Boissel N. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? Curr Opin Hematol 2009;16:92-7.
4. Hart SM, Foroni L. Core binding factor genes and human leukemia. Haematologica 2002;87:1307-23.
5. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
6. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896-903.
7. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
8. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006;20:87-94.
9. Arellano M, Bernal-Mizrachi L, Pan L, et al. Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2011;11:427-32.
10. Medd PG, Clark N, Leyden K, Turner S, Strefford JA, Butler C, Collins GP, Roberts DJ, Atoyebi W, Hatton CS. A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma. Cytometry B Clin Cytom 2011;80:230-7.
11. Mallett S, Timmer A, Sauerbrei W, Altman DG (2010) Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 102:173-80.
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93:387-91.
13. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9.
14. Grimwade D, Hills RK (2009) Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009:385-95.
15. Klepin HD, Balducci L. Acute myelogenous leukemia in older adults. Oncologist 2009;14:222-32.
16. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907.
17. Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009;27:4747-53.
18. Martin G, Barragan E, Bolufer P, Chillon C, Garcia-Sanz R, Gomez T, Brunet S, Gonzalez M, Sanz MA. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Haematologica 2000;85:699-703.
19. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002;99:3517-23.
20. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173-9.
21. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005;106:3618-20.
22. Lasa A, Carricondo MT, Carnicer MJ, Perea G, Aventin A, Nomdedeu JF. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. Haematologica 2006;91:1283-4.
23. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463-8.
24. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791-9.
25. Jiao B, Wu CF, Liang Y, et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009;23:1598-604.
26. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
27. Carella C, Bonten J, Sirma S, et al. MN1 overexpression is an important step in the development of inv(16) AML. Leukemia 2007;21:1679-90.
28. Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008;111:5371-9.
29. Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003;102:1613-8.
30. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B, Ganser A. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006;108:3898-905.
31. Baldus CD, Martus P, Burmeister T, Schwartz S, Gokbuget N, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007;25:3739-45.